Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies. This is attributed to a shortage of leukemia-specific cell-surface antigens that...

Full description

Bibliographic Details
Main Authors: Gianna M. Branella, Jasmine Y. Lee, Jennifer Okalova, Kiran K. Parwani, Jordan S. Alexander, Raquel F. Arthuzo, Andrew Fedanov, Bing Yu, David McCarty, Harrison C. Brown, Shanmuganathan Chandrakasan, Brian G. Petrich, Christopher B. Doering, H. Trent Spencer
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Immunology
Subjects:
acute myeloid leukemia (AML)
gamma delta (γδ) T cells
ligand-based therapeutics
chimeric antigen receptor (CAR)
secreted bispecific T cell engager
stem cell factor (SCF)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1294555/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1294555/full

Similar Items